Entries by drdeannaattai

Risk Reducing Medications

6 September 2019 The US Preventative Services Task Force (USPSTF) and the American Society of Clinical Oncology (ASCO) have both released updated recommendations on the use of medications (tamoxifen, raloxifene, anastrozole and exemestane) to reduce the risk of estrogen-receptor positive breast cancer in women who are considered to be at high risk for the disease. […]

, ,

Including Men in Breast Cancer Studies

3 September 2019 Last week, the US Food and Drug Administration (FDA) issued draft guidelines for industry, which encourage the inclusion of male breast cancer patients in clinical trials that evaluate breast cancer therapies. The guidelines note that “eligibility criteria for clinical trials of breast cancer drugs should allow for inclusion of both males and […]

,

USPSTF Update on BRCA Testing

23 August 2019 Earlier this week, the United States Preventative Services Task Force (USPSTF) released an updated recommendation for genetic testing for BRCA 1 and 2 mutations. Their previous guideline, released in 2013, recommended risk assessment and consideration of testing in women with a family history of breast and/or ovarian cancer. The current guidelines add consideration […]

Breast Implant Recall

24 July 2019 This morning, the US FDA announced that it was recommending that specific models of breast implants manufactured by Allergan be removed from the market due to concerns about breast implant associated anaplastic large cell lymphoma (BIA-ALCL), a form of cancer. Allergan responded by announcing a worldwide recall of BIOCELL textured breast implants. […]

,

Triple Negative Breast Cancer Disparities

14 July 2019 A study recently published in the journal Cancer* reports on disparities in triple negative breast cancer (TNBC). The researchers used the US cancer statistics database, and compared differences between TNBC and other breast cancer subtypes focusing on age, race / ethnicity, and stage at diagnosis.  Between 2010 and 2014, approximately 1.15 million […]

,

Tumor Heterogeneity and Prognosis

5 July 2019 We tend to think of most cancers as a single cell line, or clone – one normal cell develops a mutation, and that abnormal cell continues to divide. However, many tumors exhibit what is termed “heterogeneity” – meaning they are composed of cells with different genetic makeups. These cells can have different […]